<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952350</url>
  </required_header>
  <id_info>
    <org_study_id>R.21.04.1300.R1</org_study_id>
    <nct_id>NCT04952350</nct_id>
  </id_info>
  <brief_title>Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT</brief_title>
  <acronym>COVID-STAT</acronym>
  <official_title>Atorvastatin in Hospitalized COVID-19 Patients: A Randomized, Double-blinded, Placebo-Controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized placebo-controlled double-blinded clinical trial aims to test the efficacy of&#xD;
      administering atorvastatin 40 mg to hospitalized COVID-19 patients for 28 days on the&#xD;
      all-cause 28-day mortality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 14, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients, caregivers, data collectors, and data analysts will be blinded for the study group. The Delta Pharma company (Egypt) will provide the atorvastatin and a similar placebo. The company will not participate in any step of the study including participant recruitment, data collection, data analysis, or results reporting. The company will prepare a similar package of drug and placebo (labeled as A and B). Even the pharmacist involved in treatment allocation will not know what is the treatment group, just A or B. For emergency unmasking, one of the directors of the COVID19 research council, who will not participate in the study, will know the true labels and the randomization table.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>all-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of invasive mechanical ventilation (IMV)</measure>
    <time_frame>28 days or primary hospital stay</time_frame>
    <description>incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of invasive mechanical ventilation (IMV)</measure>
    <time_frame>28 days or primary hospital stay</time_frame>
    <description>duration in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>28 days or primary hospital stay</time_frame>
    <description>2 points reduction in the WHO disease ordinal progression scale or discharge, whatever happens first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse effects</measure>
    <time_frame>28 days after start of the drug</time_frame>
    <description>any event that leads to discontinuation of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care length of stay</measure>
    <time_frame>28 days or primary hospital stay</time_frame>
    <description>duration in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>28 days or primary hospital stay</time_frame>
    <description>Increase in Scr by &gt;/ 0.3 mg/ dl in 48 hr or Increase in Scr by &gt;/ 50% in 7 days or Oliguria for &gt;/ 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>status at hospital discharge</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>dead or alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>Length of hospital stay in days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>C-Reactive Protein</measure>
    <time_frame>on days 3, 7, 14, and 28 after randomization/ if still hospitalized</time_frame>
    <description>as inflammatory marker</description>
  </other_outcome>
  <other_outcome>
    <measure>Sequential Organ Failure Assessment scale</measure>
    <time_frame>on days 3, 7, 14, and 28 after randomization/ if still hospitalized</time_frame>
    <description>SOFA scale</description>
  </other_outcome>
  <other_outcome>
    <measure>COVID Disease progression score</measure>
    <time_frame>on days 3, 7, 14, and 28 after randomization/ if still hospitalized</time_frame>
    <description>according to the January 2021 WHO update</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV2 Infection</condition>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will be randomized to receive atorvastatin 40 mg once daily orally for a maximum of 28 days. All patients will receive the standard of care according to recent local hospital protocol. Antiviral treatment will be allowed and will be reported.&#xD;
Administration in unconscious or ventilated patients: The patients will receive the drug (divided into 4 quadrants) through a nasogastric tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients will be randomized to receive the placebo once daily orally for a maximum of 28 days. All patients will receive the standard of care according to recent local hospital protocol. Antiviral treatment will be allowed and will be reported.&#xD;
Administration in unconscious or ventilated patients: The patients will receive the drug through a nasogastric tube.&#xD;
Placebo will resemble the original drug as regards the drug package, the tablet color, consistency, and size.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40 Mg Oral Tablet</intervention_name>
    <description>Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>134523-00-5</other_name>
    <other_name>ATORVASTATIN CALCIUM</other_name>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  We will include adult patients (â‰¥18 years old) with severe and critical COVID19&#xD;
             admitted to the COVID19 Mansoura University isolation hospital. We will include&#xD;
             patients who are PCR-confirmed, clinically or radiologically diagnosed with COVID19.&#xD;
&#xD;
        Cases are defined as severe or critical according to the WHO definition (19); where&#xD;
        critical cases have ARDS, or sepsis, septic shock or pulmonary embolism, acute coronary&#xD;
        syndrome, or acute stroke, while severe cases have the clinical signs of severe pneumonia&#xD;
        and SpO2 &lt;90% on room air, or RR &lt;30 breaths/min without any critical criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic statin use, serum creatine kinase (sr CK) &gt; 5 times the upper limit of normal&#xD;
             (ULN), serum transaminases &gt; 5 times ULN, acute hepatic failure, chronic liver disease&#xD;
             (Child-Pugh Classification C), history of rhabdomyolysis or myopathies, severe renal&#xD;
             impairment not receiving renal replacement therapy (estimated Cr cl&lt; 30 ml\min ),&#xD;
             pregnant and lactating women, patients who are expected to die within 48 hours, or&#xD;
             patients on chronic colchicine, cyclosporines, or ritonavir.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moataz M Emara, MD, EDAIC</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University - Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University Hospitals</name>
      <address>
        <city>Mansoura</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atorvastatin</keyword>
  <keyword>randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will make the anonymous individual data available at reasonable request after publication. Patient confidentiality will be kept safe.</ipd_description>
    <ipd_time_frame>will be updtaed shortly</ipd_time_frame>
    <ipd_access_criteria>will be updated shortly</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

